Shotaro Korehisa
Kyushu University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shotaro Korehisa.
International Journal of Cancer | 2018
Shotaro Korehisa; Eiji Oki; Makoto Iimori; Yu Nakaji; Mototsugu Shimokawa; Hiroshi Saeki; Shinji Okano; Yoshinao Oda; Yoshihiko Maehara
Immunotherapy is reportedly effective in colorectal cancers (CRCs) with high microsatellite instability (MSI‐H); however, the specific cell types that respond to immune checkpoint therapy are unclear. Herein, we aimed to examine the expression of programmed cell death‐ligand 1 (PD‐L1) and related proteins in MSI‐H and microsatellite‐stable (MSS) CRCs to investigate the immune microenvironment at the tumors invasive front. The MSI status was retrospectively assessed in 499 patients undergoing surgical resection of primary CRC; of these, 48 were classified as MSI‐H. Propensity score matching was performed, and tissues from 36 and 37 patients with MSI‐H and MSS CRCs, respectively, were immunohistochemically evaluated for PD‐L1, PD‐1, CD8 and CD68. PD‐L1 expression was evaluated separately for tumor cells (PD‐L1 [T]) and tumor‐infiltrating myeloid cells in the stroma (PD‐L1 [I]). PD‐L1 (T) was positive in only 5.4% and 36.1% of MSS and MSI‐H CRCs, while PD‐L1 (I) was positive in 27% and 72.2% of these CRCs, respectively. The PD‐L1 (T) and PD‐L1 (I) expression levels in MSI‐H CRCs significantly correlated with poor differentiation, lymphatic invasion and vascular invasion (p < 0.05), and with early‐stage adenocarcinoma and high budding grade (p < 0.05), respectively. Significantly more PD‐L1 (I), CD8‐positive cells and CD68‐positive macrophages were present at the invasive front than in the central tumor in MSI‐H CRCs (p < 0.005). PD‐L1 was expressed on both tumor cells and CD68/CD163‐positive (M2) macrophages at the invasive front of MSI‐H CRCs. In conclusion, PD‐L1‐positive tumor cells and M2‐type tumor‐associated macrophages may contribute to tumor invasion and immune escape at the invasive front.
Surgical Case Reports | 2018
Tetsuro Kawazoe; Hiroshi Saeki; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Kensuke Kudou; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Yuichiro Nakashima; Eiji Oki; Minako Fujiwara; Yoshinao Oda; Yoshihiko Maehara
BackgroundMixed adenoneuroendocrine carcinoma (MANEC) is defined as a neoplasm composed of both exocrine and endocrine carcinomas, each comprising at least 30% of the tumor. MANEC can occur in various organs of the gastrointestinal tract, including the esophagus, stomach, and colon. We herein provide the first case report of surgically resected MANEC arising in Barrett’s esophagus (BE).Case presentationA 70-year-old man presenting with abdominal pain was referred to our hospital. Upper endoscopy showed a type 0-IIa + IIc elevated lesion adjacent to BE. According to a biopsy specimen, the elevated lesion was diagnosed as adenocarcinoma with neuroendocrine differentiation. No lymphatic or distant metastasis was detected in the preoperative examination. Laparoscopic distal esophagectomy and proximal gastrectomy were performed, and a diagnosis of MANEC in BE was determined according to the surgically resected specimen.ConclusionsA very rare case of MANEC in BE was detected. BE can be the origin of esophageal MANEC as well as adenocarcinoma. Due to the small number of esophageal or esophagogastric MANEC cases reported, further accumulation of such cases is necessary to recommend an optimal management strategy for esophageal or esophagogastric MANEC.
Histopathology | 2018
Shotaro Korehisa; Tetsuo Ikeda; Shinji Okano; Hiroshi Saeki; Eiji Oki; Yoshinao Oda; Makoto Hashizume; Yoshihiko Maehara
Programmed cell death‐ligand 1 (PD‐L1) expression is observed in patients with microsatellite instability‐high (MSI‐H) colon cancer, which is susceptible to immune checkpoint blockade. The aim of this study was to investigate the interrelationship between PD‐L1‐positive cells and cytotoxic T cells, lymphatic vessels and vascular endothelium by using histological examination with the three‐dimensional (3D) reconstruction of a PD‐L1‐positive colon cancer.
Annals of Surgical Oncology | 2017
Kensuke Kudou; Hiroshi Saeki; Yuichiro Nakashima; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Ryosuke Tsutsumi; Sho Nishimura; Yu Nakaji; Shingo Akiyama; Hirotada Tajiri; Ryota Nakanishi; Junji Kurashige; Masahiko Sugiyama; Eiji Oki; Yoshihiko Maehara
Surgery Today | 2018
Ryota Nakanishi; Eiji Oki; Shun Sasaki; Kosuke Hirose; Tomoko Jogo; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Kensuke Kudo; Junji Kurashige; Masahiko Sugiyama; Yuichiro Nakashima; Kippei Ohgaki; Hiroshi Saeki; Yoshihiko Maehara
World Journal of Surgery | 2018
Hiroshi Saeki; Yuichiro Nakashima; Kensuke Kudou; Shun Sasaki; Tomoko Jogo; Kosuke Hirose; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Akira Kabashima; Eiji Oki; Yoshihiko Maehara
Diseases of The Esophagus | 2018
Hiroshi Saeki; Yuichiro Nakashima; Nobuhide Kubo; Kosuke Hirose; Shun Sasaki; Tomoko Jogo; Daisuke Taniguchi; Keitaro Edahiro; Shotaro Korehisa; Ryota Nakanishi; Koji Ando; Eiji Oki; Yoshihiko Maehara
Anticancer Research | 2017
Yoshiaki Fujimoto; Yuichiro Nakashima; Shun Sasaki; Tomoko Jogo; Kosuke Hirose; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Kensuke Kudou; Yu Nakaji; Ryota Nakanishi; Koji Ando; Hiroshi Saeki; Eiji Oki; Minako Fujiwara; Yoshinao Oda; Yoshihiko Maehara
American Journal of Surgery | 2017
Hiroshi Saeki; Yuichiro Nakashima; Kosuke Hirose; Shun Sasaki; Tomoko Jogo; Daisuke Taniguchi; Keitaro Edahiro; Shotaro Korehisa; Kensuke Kudou; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Akira Kabashima; Eiji Oki; Yoshihiko Maehara
/data/revues/00029610/unassign/S0002961017312904/ | 2017
Hiroshi Saeki; Yuichiro Nakashima; Kosuke Hirose; Shun Sasaki; Tomoko Jogo; Daisuke Taniguchi; Keitaro Edahiro; Shotaro Korehisa; Kensuke Kudou; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Akira Kabashima; Eiji Oki; Yoshihiko Maehara